ASCO Annual Meeting | Conference

Anti-CD47 Antibody Plus Rituximab Demonstrates Efficacy in Half of Patients With Relapsed/Refractory NHL

June 4th 2018

Half of a small group of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) had major responses to treatment with an anti-CD47 antibody plus rituximab (Rituxan).

Pegilodecakin Plus PD-1 Inhibitor Shows Potential in NSCLC

June 4th 2018

Combining pegilodecakin with nivolumab or pembrolizumab induced an overall response rate of 41% in patients with advanced non–small cell lung cancer.

Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

June 4th 2018

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

Erdafitinib Active in Advanced Metastatic Urothelial Carcinoma

June 4th 2018

More than 40% of patients with metastatic or unresectable urothelial carcinoma responded to treatment with an investigational fibroblast growth factor receptor inhibitor.

Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC

June 4th 2018

First-line treatment with the oral AKT inhibitor ipatasertib shows a promising trend toward improving overall survival when added to paclitaxel for the treatment of locally advanced or metastatic triple-negative breast cancer.

Ribociclib Prolongs PFS With Fulvestrant in First- or Second-Line HR-Positive, HER2-Negative Advanced Breast Cancer

June 3rd 2018

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly prolonged progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no or 1 prior line of therapy.

Lenvatinib-Pembrolizumab Combo Has Promising Activity in Squamous Cell Head and Neck Cancer

June 3rd 2018

Lenvatinib added to pembrolizumab demonstrated promising activity in patients with squamous cell carcinoma of the head and neck in an ongoing open-label phase Ib/II clinical trial.

Pembrolizumab Plus Chemo Emerges as New Standard in Frontline Squamous NSCLC

June 3rd 2018

Adding pembrolizumab to frontline carboplatin/paclitaxel or nab-paclitaxel reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic squamous non–small cell lung cancer.

Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score

June 3rd 2018

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Sunitinib Noninferior to Surgery for OS in Metastatic Kidney Cancer

June 3rd 2018

Sunitinib alone was noninferior to cytoreductive nephrectomy plus sunitinib, the current standard of care, in patients with synchronous metastatic renal cell carcinoma.

Maintenance Therapy Changes Paradigm in Rare Childhood Sarcoma

June 3rd 2018

A course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy led to significant improvements in disease-free and overall survival in pediatric rhabdomyosarcoma.

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

June 3rd 2018

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study

June 3rd 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma

June 3rd 2018

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

cfDNA Assays Demonstrate High Specificity for Early Stage Lung Cancer Detection

June 2nd 2018

Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.

Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma

June 2nd 2018

Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.

Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers

June 2nd 2018

Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.

Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer

June 2nd 2018

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma

June 2nd 2018

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.